This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Investigating the Effect of Telmisartan (Micardis®) on the Average 24h Blood Pressure of Therapy-naive and Therapy-experienced Patients

This study has been completed.
Information provided by (Responsible Party):
Boehringer Ingelheim Identifier:
First received: April 9, 2009
Last updated: February 28, 2014
Last verified: February 2014
Practical experience report (PER) investigating the effect of Micardis® on the average 24h blood pressure of therapy-naive and therapy-experienced patients

Condition Intervention
Hypertension Drug: Micardis

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: 24h BP Under Micardis in Daily Practice

Resource links provided by NLM:

Further study details as provided by Boehringer Ingelheim:

Primary Outcome Measures:
  • Efficacy (Change of Systolic Blood Pressure) [ Time Frame: baseline to 8 weeks ]
    Change from baseline in 24h systolic blood pressure (BP) at week 8

  • Efficacy (Change of Diastolic Blood Pressure) [ Time Frame: baseline to 8 weeks ]
    Change from baseline in 24h diastolic blood pressure (BP) at week 8

Secondary Outcome Measures:
  • Overall Tolerability Scale [ Time Frame: 8 weeks ]
    Safety and tolerability of Micardis® in the treatment of patients with hypertension over 8 weeks, using 10 point Likert scale with worst score=1, best score=10

Enrollment: 670
Study Start Date: April 2009
Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
arterial hypertension Drug: Micardis


Ages Eligible for Study:   18 Years to 95 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
hypertensive patients

Inclusion criteria:

  1. Patients who have recently been diagnosed with hypertension
  2. Patients whose current blood pressure treatment are inadequate and needs to be revised are suitable for inclusion.

Exclusion criteria:

None (according to investigator)

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00879411

Sponsors and Collaborators
Boehringer Ingelheim
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
  More Information

Responsible Party: Boehringer Ingelheim Identifier: NCT00879411     History of Changes
Other Study ID Numbers: 502.582
Study First Received: April 9, 2009
Results First Received: January 18, 2012
Last Updated: February 28, 2014

Additional relevant MeSH terms:
Antihypertensive Agents
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action processed this record on September 21, 2017